Search

Your search keyword '"Antonioli, Elisabetta"' showing total 15 results
Start Over Author "Antonioli, Elisabetta" Publisher wiley
15 results on '"Antonioli, Elisabetta"'

1. Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: A retro‐prospective observational study

Author

Del Giudice, Maria Livia, primary, Gozzetti, Alessandro, additional, Antonioli, Elisabetta, additional, Attucci, Irene, additional, Pengue, Ludovica, additional, Cassano Cassano, Raffaella, additional, Ghio, Francesco, additional, Orciuolo, Enrico, additional, Simoncelli, Martina, additional, Bocchia, Monica, additional, Galimberti, Sara, additional, and Buda, Gabriele, additional

Published
2022
Full Text
View/download PDF

2. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials

Author

Bruzzese, Antonella, primary, Derudas, Daniele, additional, Galli, Monica, additional, Martino, Enrica Antonia, additional, Rocco, Stefano, additional, Conticello, Concetta, additional, Califano, Catello, additional, Giuliani, Nicola, additional, Mangiacavalli, Silvia, additional, Farina, Giuliana, additional, Lombardo, Alessandra, additional, Brunori, Marino, additional, Rossi, Elena, additional, Antonioli, Elisabetta, additional, Ria, Roberto, additional, Zambello, Renato, additional, Di Renzo, Nicola, additional, Mele, Giuseppe, additional, Marcacci, Gianpaolo, additional, Pietrantuono, Giuseppe, additional, Palumbo, Gaetano, additional, Cascavilla, Nicola, additional, Cerchione, Claudio, additional, Belotti, Angelo, additional, Criscuolo, Clelia, additional, Uccello, Giuseppina, additional, Curci, Paola, additional, Vigna, Ernesto, additional, Mendicino, Francesco, additional, Iaccino, Enrico, additional, Mimmi, Selena, additional, Botta, Cirino, additional, Vincelli, Donatella, additional, Sgherza, Nicola, additional, Bonalumi, Angela, additional, Cupelli, Luca, additional, Stocchi, Raffaella, additional, Martino, Massimo, additional, Ballanti, Stelvio, additional, Gangemi, Dominella, additional, Gagliardi, Alfredo, additional, Gamberi, Barbara, additional, Pompa, Alessandra, additional, Tripepi, Giovanni, additional, Frigeri, Ferdinando, additional, Consoli, Ugo, additional, Bringhen, Sara, additional, Zamagni, Elena, additional, Patriarca, Francesca, additional, De Stefano, Valerio, additional, Di Raimondo, Francesco, additional, Palmieri, Salvatore, additional, Petrucci, Maria Teresa, additional, Offidani, Massimo, additional, Musto, Pellegrino, additional, Boccadoro, Mario, additional, Cavo, Michele, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, and Gentile, Massimo, additional

Published
2022
Full Text
View/download PDF

3. Ventricular tachyarrhythmias and sudden cardiac death in light‐chain amyloidosis: a clash of cardio‐toxicities?

Author

Zampieri, Mattia, primary, Allinovi, Marco, additional, Olivotto, Iacopo, additional, Antonioli, Elisabetta, additional, Gabriele, Martina, additional, Argirò, Alessia, additional, Fumagalli, Carlo, additional, Nardi, Giulia, additional, Di Mario, Carlo, additional, Vannucchi, Alessandro M., additional, Perfetto, Federico, additional, and Cappelli, Francesco, additional

Published
2021
Full Text
View/download PDF

5. A real‐world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma

Author

Rocchi, Serena, primary, Tacchetti, Paola, additional, Pantani, Lucia, additional, Mancuso, Katia, additional, Rizzello, Ilaria, additional, di Giovanni Bezzi, Chiara, additional, Scalese, Marco, additional, Dozza, Luca, additional, Marzocchi, Giulia, additional, Martello, Marina, additional, Barilà, Gregorio, additional, Antonioli, Elisabetta, additional, Staderini, Michela, additional, Buda, Gabriele, additional, Petrini, Mario, additional, Cea, Michele, additional, Quaresima, Micol, additional, Furlan, Anna, additional, Bonalumi, Angela, additional, Cavo, Michele, additional, and Zamagni, Elena, additional

Published
2020
Full Text
View/download PDF

7. Pregnancy complications predict thrombotic events in young women with essential thrombocythemia

Author

Randi, Maria Luigia, primary, Bertozzi, Irene, additional, Rumi, Elisa, additional, Elena, Chiara, additional, Finazzi, Guido, additional, Vianelli, Nicola, additional, Polverelli, Nicola, additional, Ruggeri, Marco, additional, Vannucchi, Alessandro Maria, additional, Antonioli, Elisabetta, additional, Lussana, Federico, additional, Tieghi, Alessia, additional, Iurlo, Alessandra, additional, Elli, Elena, additional, Ruella, Marco, additional, Fabris, Fabrizio, additional, Cazzola, Mario, additional, and Barbui, Tiziano, additional

Published
2014
Full Text
View/download PDF

8. Leukocytosis as an important risk factor for arterial thrombosis in WHO‐defined early/prefibrotic myelofibrosis: An international study of 264 patients

Author

Buxhofer‐Ausch, Veronika, primary, Gisslinger, Heinz, additional, Thiele, Jürgen, additional, Gisslinger, Bettina, additional, Kvasnicka, Hans‐Michael, additional, Müllauer, Leonhard, additional, Frantal, Sophie, additional, Carobbio, Alessandra, additional, Passamonti, Francesco, additional, Rumi, Elisa, additional, Ruggeri, Marco, additional, Rodeghiero, Francesco, additional, Randi, Maria L., additional, Bertozzi, Irene, additional, Vannucchi, Alessandro M., additional, Antonioli, Elisabetta, additional, Finazzi, Guido, additional, Gangat, Naseema, additional, Tefferi, Ayalew, additional, and Barbui, Tiziano, additional

Published
2012
Full Text
View/download PDF

9. Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia

Author

Carobbio, Alessandra, primary, Finazzi, Guido, additional, Thiele, Juergen, additional, Kvasnicka, Hans-Michael, additional, Passamonti, Francesco, additional, Rumi, Elisa, additional, Ruggeri, Marco, additional, Rodeghiero, Francesco, additional, Luigia Randi, Maria, additional, Bertozzi, Irene, additional, Vannucchi, Alessandro M., additional, Antonioli, Elisabetta, additional, Gisslinger, Heinz, additional, Buxhofer-Ausch, Veronika, additional, Gangat, Naseema, additional, Rambaldi, Alessandro, additional, Tefferi, Ayalew, additional, and Barbui, Tiziano, additional

Published
2012
Full Text
View/download PDF

14. PRV-1 , erythroid colonies and platelet Mpl are unrelated to thrombosis in essential thrombocythaemia

Author

Vannucchi, Alessandro M., primary, Grossi, Alberto, additional, Pancrazzi, Alessandro, additional, Antonioli, Elisabetta, additional, Guglielmelli, Paola, additional, Balestri, Francesca, additional, Biscardi, Monica, additional, Bulgarelli, Simona, additional, Longo, Giovanni, additional, Graziano, Claudio, additional, Gugliotta, Luigi, additional, and Bosi, Alberto, additional

Published
2004
Full Text
View/download PDF

15. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials

Author

Antonella Bruzzese, Daniele Derudas, Monica Galli, Enrica Antonia Martino, Stefano Rocco, Concetta Conticello, Catello Califano, Nicola Giuliani, Silvia Mangiacavalli, Giuliana Farina, Alessandra Lombardo, Marino Brunori, Elena Rossi, Elisabetta Antonioli, Roberto Ria, Renato Zambello, Nicola Di Renzo, Giuseppe Mele, Gianpaolo Marcacci, Giuseppe Pietrantuono, Gaetano Palumbo, Nicola Cascavilla, Claudio Cerchione, Angelo Belotti, Clelia Criscuolo, Giuseppina Uccello, Paola Curci, Ernesto Vigna, Francesco Mendicino, Enrico Iaccino, Selena Mimmi, Cirino Botta, Donatella Vincelli, Nicola Sgherza, Angela Bonalumi, Luca Cupelli, Raffaella Stocchi, Massimo Martino, Stelvio Ballanti, Dominella Gangemi, Alfredo Gagliardi, Barbara Gamberi, Alessandra Pompa, Giovanni Tripepi, Ferdinando Frigeri, Ugo Consoli, Sara Bringhen, Elena Zamagni, Francesca Patriarca, Valerio De Stefano, Francesco Di Raimondo, Salvatore Palmieri, Maria Teresa Petrucci, Massimo Offidani, Pellegrino Musto, Mario Boccadoro, Michele Cavo, Antonino Neri, Fortunato Morabito, Massimo Gentile, Bruzzese, Antonella, Derudas, Daniele, Galli, Monica, Martino, Enrica Antonia, Rocco, Stefano, Conticello, Concetta, Califano, Catello, Giuliani, Nicola, Mangiacavalli, Silvia, Farina, Giuliana, Lombardo, Alessandra, Brunori, Marino, Rossi, Elena, Antonioli, Elisabetta, Ria, Roberto, Zambello, Renato, Di Renzo, Nicola, Mele, Giuseppe, Marcacci, Gianpaolo, Pietrantuono, Giuseppe, Palumbo, Gaetano, Cascavilla, Nicola, Cerchione, Claudio, Belotti, Angelo, Criscuolo, Clelia, Uccello, Giuseppina, Curci, Paola, Vigna, Ernesto, Mendicino, Francesco, Iaccino, Enrico, Mimmi, Selena, Botta, Cirino, Vincelli, Donatella, Sgherza, Nicola, Bonalumi, Angela, Cupelli, Luca, Stocchi, Raffaella, Martino, Massimo, Ballanti, Stelvio, Gangemi, Dominella, Gagliardi, Alfredo, Gamberi, Barbara, Pompa, Alessandra, Tripepi, Giovanni, Frigeri, Ferdinando, Consoli, Ugo, Bringhen, Sara, Zamagni, Elena, Patriarca, Francesca, De Stefano, Valerio, Di Raimondo, Francesco, Palmieri, Salvatore, Petrucci, Maria Teresa, Offidani, Massimo, Musto, Pellegrino, Boccadoro, Mario, Cavo, Michele, Neri, Antonino, Morabito, Fortunato, and Gentile, Massimo

Subjects
Cancer Research, lenalidomide, dexamethasone, elotuzumab, multiple myeloma, salvage therapy, Hematology, General Medicine, Antibodies, Monoclonal, Humanized, Thalidomide, Oncology, Antineoplastic Combined Chemotherapy Protocols, Humans, Settore MED/15 - Malattie del Sangue, Follow-Up Studies, Retrospective Studies
Abstract

The combination of elotuzumab, lenalidomide, and dexamethasone (EloRd) enhanced the clinical benefit over Rd with a manageable toxicity profile in the ELOQUENT-2 trial, leading to its approval in relapsed/refractory multiple myeloma (RRMM). The present study is a 3-year follow-up update of a previously published Italian real-life RRMM cohort of patients treated with EloRd. This revised analysis entered 319 RRMM patients accrued in 41 Italian centers. After a median follow-up of 36 months (range 6-55), 236 patients experienced disease progression or died. Median progression-free survival (PFS) and overall survival (OS) were 18.4 and 34 months, respectively. The updated multivariate analyses showed a significant reduction of PFS and OS benefit magnitude only in cases with ISS stage III. Major adverse events included grade 3/4 neutropenia (18.5%), anemia (15.4%), lymphocytopenia (12.5%), and thrombocytopenia (10.7%), while infection rates and pneumonia were 33.9% and 18.9%, respectively. No new safety signals with longer follow-up have been observed. Of 319 patients, 245 (76.7%) reached at least a partial remission. A significantly lower response rate was found in patients previously exposed to lenalidomide. In conclusion, our study confirms that EloRd is a safe and effective regimen for RRMM patients, maintaining benefits across multiple unfavorable subgroups. This article is protected by copyright. All rights reserved.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results